XML 77 R67.htm IDEA: XBRL DOCUMENT v3.20.2
License and Other Agreements - AstraZeneca Agreement (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Sep. 30, 2018
USD ($)
shares
May 31, 2017
shares
Oct. 31, 2016
USD ($)
$ / shares
shares
Mar. 31, 2020
USD ($)
Jun. 30, 2019
USD ($)
Jun. 30, 2020
USD ($)
Jun. 30, 2019
USD ($)
Dec. 31, 2017
USD ($)
License and other agreements                
Value of common stock issued       $ 282,833 $ 281,100      
Payment for license agreement           $ 21,500 $ 0  
AstraZeneca | License Agreement                
License and other agreements                
Payment for license agreement $ 3,000              
Issuance of common shares as payment for assets (in shares) | shares 109,523              
Issuance of common shares as payment for assets $ 4,080              
Milestone payment due upon achievement of specified regulatory and commercial milestones 55,000              
Milestone payment due upon achievement of specified sales-based milestones $ 50,000              
Agreement time period 10 years              
AstraZeneca | Collaborative arrangement                
License and other agreements                
Expiration period based on country by country basis after first commercial sale (in years)     10 years          
Common stock value agreed to issue     $ 10,000          
Value of common stock issued     $ 5,000          
Percentage of shares to be issued upon closing of the transaction     0.50          
Percentage of remaining shares to be issued after contractual events     0.50          
Fair value of common share | $ / shares     $ 9.2911          
Preferred stock issued and sold (in shares) | shares     538,150          
Aggregate fair value     $ 5,000          
Reclassifications of contingent equity to carrying value     5,000          
Common stock issued (shares) | shares   538,150            
Change in fair value of contingent equity liability               $ 4,273
AstraZeneca | Collaborative arrangement | Maximum                
License and other agreements                
Milestone payment to be paid upon regulatory achievement     30,000          
Milestone payment to be paid for any product other than rimegepant     60,000          
Commercial milestone payment to be paid     $ 120,000          
Right to purchase shares fully diluted (as a percent)     0.08          
AstraZeneca | Collaborative arrangement | Minimum                
License and other agreements                
Minimum investment in equity     $ 30,000